Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

被引：0
|
作者：
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Esposti, Simona Degli
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Univ Coll London Hosp, NHS Fdn Trust, London, England
[4] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[7] UCL Inst Ophthalmol, London, England
[8] GlaxoSmithKline, Res Triangle Pk, NC USA
[9] GlaxoSmithKline, Upper Providence, PA USA
[10] GlaxoSmithKline, Zug, Switzerland
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：4
相关论文
共 34 条
  • [1] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Degli Esposti, Simona
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
  • [2] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)
    Kortuem, M.
    Terpos, E.
    Badros, A.
    Popat, R.
    Rodriguez-Otero, P.
    Farooq, A.
    Jeng, B.
    Esposti, Degli S.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    Palumbo, A.
    Trudel, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 204
  • [3] Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin
    Terpos, Evangelos
    Badros, Ashraf Z.
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim V.
    Jeng, Bennie
    Esposti, Simona Degli
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    Jadhav, Vinay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S160 - S160
  • [4] Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Degli Esposti, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S30 - S30
  • [5] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [6] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [7] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Sagar Lonial
    Ajay K. Nooka
    Praneetha Thulasi
    Ashraf Z. Badros
    Bennie H. Jeng
    Natalie S. Callander
    Heather A. Potter
    Douglas Sborov
    Brian E. Zaugg
    Rakesh Popat
    Simona Degli Esposti
    Julie Byrne
    Joanna Opalinska
    January Baron
    Trisha Piontek
    Ira Gupta
    Reza Dana
    Asim V. Farooq
    Kathryn Colby
    Andrzej Jakubowiak
    Blood Cancer Journal, 11
  • [8] LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Collins, J.
    van Noort, M.
    Rathi, C.
    Post, T.
    Struemper, H.
    Jewell, R.
    Ferron-Brady, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S16 - S17
  • [9] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Baron, January
    Doherty, Allison
    Lewis, Eric
    Opalinska, Joanna
    Paka, Prani
    Piontek, Trisha
    Gupta, Ira
    Farooq, Asim V.
    Jakubowiak, Andrzej
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
  • [10] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
    Trautmann-Grill, K.
    Lonial, S.
    Nooka, A. K.
    Thulasi, P.
    Badros, A. Z.
    Jeng, B. H.
    Callander, N. S.
    Sborov, D.
    Zaugg, B. E.
    Popat, R.
    Degli, Esposti S.
    Baron, J.
    Doherty, A.
    Lewis, E.
    Opalinska, J.
    Paka, P.
    Piontek, T.
    Gupta, I
    Farooq, A., V
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
1234